1. Scrip
  2. >>Business

India Pharma Action: GMP Enforcement, CDMO Rage And Private Equity Interest

 
• By Anju Ghangurde

In this second instalment on key trends playing out in India, Scrip talks to industry leaders on the marked shift in GMP norms that could potentially resize Indian manufacturing, large player interest in the CDMO space and M&A activity, where PE firms may be the “most aggressive” buyers.

Two wooden cogs
Spotlight On Compliance, CDMOs And M&A in India • Source: Shutterstock

The year gone by had its see-saw moments for the Indian pharmaceutical industry.

The arrival of an indigenously developed CAR-T cell therapy in India was among the highlights of 2023, but exports of contaminated cough syrups raised many uncomfortable questions in a sector that prides itself as the pharmacy to the world

Key Takeaways

  • Action seen in compliance arena, CDMO segment, M&A

  • Revised GMP norms could resize 10,000-plus unit Indian manufacturing

  • Frontline firms eye share of CDMO pie including for large molecules

  • Dr Reddy’s, Lupin, Aurobindo among those building out CDMO plans

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.